Related Experiment Videos
Cytokine directed therapy in scleroderma: rationale, current status, and the future
Robert W Simms1, Joseph H Korn
1Rheumatology Section, Department of Medicine, Boston University School of Medicine, Massachusetts, USA. rsimms@medicine.bu.edu
Current Opinion in Rheumatology
|November 1, 2002
Summary
Scleroderma involves fibrosis due to increased matrix proteins. Targeting cytokines like transforming growth factor beta (TGF-beta) offers a promising therapeutic strategy for fibrotic diseases.
Area of Science:
- Immunology
- Dermatology
- Fibrosis Research
Background:
- Scleroderma is characterized by excessive fibrosis in skin and organs.
- Fibrosis results from increased matrix protein synthesis by interstitial fibroblasts.
Purpose of the Study:
- To review cytokines involved in scleroderma and other fibrotic conditions.
- To explore potential therapeutic targets for fibrotic diseases.
Main Methods:
- Literature review of cytokines and their roles in fibrosis.
- Analysis of animal studies and existing anticytokine therapies.
Main Results:
- Cytokines are key extracellular mediators regulating fibrosis.
- Several cytokines, including TGF-beta and CTGF, are implicated in scleroderma.
Conclusions:
- Inhibiting profibrotic cytokines or promoting antifibrotic cytokines is a viable therapeutic approach.
- Targeting specific cytokines presents a rational strategy for treating scleroderma and other fibrotic diseases.